LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 171

Search options

  1. Article: Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?

    Vervloet, Marc G

    Clinical kidney journal

    2023  Volume 16, Issue 11, Page(s) 1766–1775

    Abstract: The increased cardiovascular risk of chronic kidney disease may in part be the consequence of arterial stiffness, a typical feature of kidney failure. Deranged homeostasis of minerals and hormones involved (CKD-MBD), are also strongly associated with ... ...

    Abstract The increased cardiovascular risk of chronic kidney disease may in part be the consequence of arterial stiffness, a typical feature of kidney failure. Deranged homeostasis of minerals and hormones involved (CKD-MBD), are also strongly associated with this increased risk. It is well established that CKD-MBD is a main driver of vascular calcification, which in turn worsens arterial stiffness. However, there are other contributors to arterial stiffness in CKD than calcification. An overlooked possibility is that CKD-MBD may have detrimental effects on this potentially better modifiable component of arterial stiffness. In this review, the individual contributions of short-term changes in calcium, phosphate, PTH, vitamin D, magnesium, and FGF23 to arterial stiffness, in most studies assessed as pulse wave velocity, is summarized. Indeed, there is evidence from both observational studies and interventional trials that higher calcium concentrations can worsen arterial stiffness. This, however, has not been shown for phosphate, and it seems unlikely that, apart from being a contributor to vascular calcification and having effects on the microcirculation, phosphate has no acute effect on large artery stiffness. Several interventional studies, both by infusing PTH and by abrupt lowering PTH by calcimimetics or surgery, virtually ruled out direct effects on large artery stiffness. A well-designed trial using both active and nutritional vitamin D as intervention found a beneficial effect for the latter. Unfortunately, the study had a baseline imbalance and other studies did not support its finding. Both magnesium and FGF23 do not seem do modify central arterial stiffness.
    Language English
    Publishing date 2023-05-15
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2655800-2
    ISSN 2048-8513 ; 2048-8505
    ISSN (online) 2048-8513
    ISSN 2048-8505
    DOI 10.1093/ckj/sfad112
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Shedding Light on the Complex Regulation of FGF23.

    Vervloet, Marc G

    Metabolites

    2022  Volume 12, Issue 5

    Abstract: Early research has suggested a rather straightforward relation between phosphate exposure, increased serum FGF23 (Fibroblast Growth Factor 23) concentrations and clinical endpoints. Unsurprisingly, however, subsequent studies have revealed a much more ... ...

    Abstract Early research has suggested a rather straightforward relation between phosphate exposure, increased serum FGF23 (Fibroblast Growth Factor 23) concentrations and clinical endpoints. Unsurprisingly, however, subsequent studies have revealed a much more complex interplay between autocrine and paracrine factors locally in bone like PHEX and DMP1, concentrations of minerals in particular calcium and phosphate, calciprotein particles, and endocrine systems like parathyroid hormone PTH and the vitamin D system. In addition to these physiological regulators, an expanding list of disease states are shown to influence FGF23 levels, usually increasing it, and as such increase the burden of disease. While some of these physiological or pathological factors, like inflammatory cytokines, may partially confound the association of FGF23 and clinical endpoints, others are in the same causal path, are targetable and hence hold the promise of future treatment options to alleviate FGF23-driven toxicity, for instance in chronic kidney disease, the FGF23-associated disease with the highest prevalence by far. These factors will be reviewed here and their relative importance described, thereby possibly opening potential means for future therapeutic strategies.
    Language English
    Publishing date 2022-04-28
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662251-8
    ISSN 2218-1989
    ISSN 2218-1989
    DOI 10.3390/metabo12050401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Magnesium Administration in Chronic Kidney Disease.

    Vermeulen, Emma A / Vervloet, Marc G

    Nutrients

    2023  Volume 15, Issue 3

    Abstract: Awareness of the clinical relevance of magnesium in medicine has increased over the last years, especially for people with chronic kidney disease (CKD), due to magnesium's role in vascular calcification and mineral metabolism. The inverse association ... ...

    Abstract Awareness of the clinical relevance of magnesium in medicine has increased over the last years, especially for people with chronic kidney disease (CKD), due to magnesium's role in vascular calcification and mineral metabolism. The inverse association between serum magnesium and clinically relevant, adverse outcomes is well-established in people with CKD. Subsequent intervention studies have focused on the effect of magnesium administration, mainly in relation to cardiovascular diseases, mineral bone metabolism, and other metabolic parameters. The most commonly used routes of magnesium administration are orally and by increasing dialysate magnesium. Several oral magnesium formulations are available and the daily dosage of elemental magnesium varies highly between studies, causing considerable heterogeneity. Although data are still limited, several clinical studies demonstrated that magnesium administration could improve parameters of vascular function and calcification and mineral metabolism in people with CKD. Current clinical research has shown that magnesium administration in people with CKD is safe, without concerns for severe hypermagnesemia or negative interference with bone metabolism. It should be noted that there are several ongoing magnesium intervention studies that will contribute to the increasing knowledge on the potential of magnesium administration in people with CKD.
    MeSH term(s) Humans ; Magnesium ; Renal Insufficiency, Chronic/complications ; Cardiovascular Diseases/etiology ; Minerals ; Vascular Calcification/complications
    Chemical Substances Magnesium (I38ZP9992A) ; Minerals
    Language English
    Publishing date 2023-01-20
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu15030547
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book ; Online ; E-Book: Vitamin D in chronic kidney disease

    Ureña Torres, Pablo A. / Cozzolino, Mario / Vervloet, Marc G.

    2016  

    Author's details Pablo A. Ureña Torres, Mario Cozzolino, Marc G. Vervloet editors
    Keywords Renal Insufficiency, Chronic / metabolism ; Vitamin D / metabolism ; Vitamin D / therapeutic use ; Vitamin D Deficiency / epidemiology ; Chronic Kidney Disease-Mineral and Bone Disorder / metabolism
    Language English
    Size 1 Online-Ressource (xxviii, 574 Seiten), Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019457447
    ISBN 978-3-319-32507-1 ; 9783319325057 ; 3-319-32507-8 ; 3319325051
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  5. Article ; Online: FGF23 measurement in chronic kidney disease: What is it really reflecting?

    Vervloet, Marc G

    Clinica chimica acta; international journal of clinical chemistry

    2020  Volume 505, Page(s) 160–166

    Abstract: Fibroblast growth factor can be measured in clinical practice using ELISA, with acceptable validity. Different from many metabolites and minerals, its value can differ by a thousand-fold between individuals, largely because of differences in kidney ... ...

    Abstract Fibroblast growth factor can be measured in clinical practice using ELISA, with acceptable validity. Different from many metabolites and minerals, its value can differ by a thousand-fold between individuals, largely because of differences in kidney function and dietary habits. This wide range complicates the proper interpretation of the concentration of FGF23, both in terms of the appropriateness of a given value for a given estimated GFR, and in terms of estimating the magnitude of risk for clinical events, with which FGF23 is clearly associated. In this narrative review, the impact of kidney function, exposure to phosphate from diet, and novel emerging factors that influence FGF23 concentrations are discussed. These and yet to define determinants of FGF23 question the causality of the association of FGF23 with hard (cardiovascular) endpoints, as observed in several epidemiological studies.
    MeSH term(s) Animals ; Biomarkers ; Fibroblast Growth Factors/analysis ; Fibroblast Growth Factors/metabolism ; Humans ; Kidney Function Tests ; Renal Insufficiency, Chronic/metabolism ; Renal Insufficiency, Chronic/physiopathology
    Chemical Substances Biomarkers ; Fibroblast Growth Factors (62031-54-3) ; fibroblast growth factor 23 (7Q7P4S7RRE)
    Language English
    Publishing date 2020-03-07
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 80228-1
    ISSN 1873-3492 ; 0009-8981
    ISSN (online) 1873-3492
    ISSN 0009-8981
    DOI 10.1016/j.cca.2020.03.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Vitamin D in CKD: An Unfinished Story.

    Hsu, Simon / Vervloet, Marc G / de Boer, Ian H

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2023  Volume 82, Issue 5, Page(s) 512–514

    Language English
    Publishing date 2023-09-16
    Publishing country United States
    Document type Editorial
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2023.07.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Chronic kidney disease-mineral and bone disorder: changing insights form changing parameters?

    Vervloet, Marc G

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2019  Volume 35, Issue 3, Page(s) 385–389

    MeSH term(s) Bone and Bones ; Chronic Kidney Disease-Mineral and Bone Disorder ; Cohort Studies ; Humans ; Minerals ; Renal Dialysis
    Chemical Substances Minerals
    Language English
    Publishing date 2019-05-18
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfz113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Vitamin D supplementation in people with chronic kidney disease.

    Vervloet, Marc G / Hsu, Simon / de Boer, Ian H

    Kidney international

    2023  Volume 104, Issue 4, Page(s) 698–706

    Abstract: Vitamin D supplements have long been advocated for people with chronic kidney disease based on data from observational studies among the general population and people with chronic kidney disease. These data consistently suggested that higher circulating ... ...

    Abstract Vitamin D supplements have long been advocated for people with chronic kidney disease based on data from observational studies among the general population and people with chronic kidney disease. These data consistently suggested that higher circulating concentrations of 25-hydroxyvitamin D are associated with improved fracture, cardiovascular, cancer, and mortality outcomes. In the past few years, large clinical trials have been conducted to assess the effects of vitamin D supplements on a range of clinically relevant outcomes. Most of these studies were performed in the general population, but they also enrolled people with chronic kidney disease. Virtually all of these trials were negative and contradicted the observational data. In this review, the key observational data and clinical trials are summarized, and potential explanations for the discrepancies between these studies are discussed.
    MeSH term(s) Humans ; Dietary Supplements ; Fractures, Bone ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Vitamin D/therapeutic use ; Observational Studies as Topic
    Chemical Substances Vitamin D (1406-16-2)
    Language English
    Publishing date 2023-08-02
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2023.07.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Hyperphosphataemia: which phosphate binder?

    Vervloet, Marc G

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2018  Volume 33, Issue 7, Page(s) 1091–1093

    Language English
    Publishing date 2018-04-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfy091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications.

    Vervloet, Marc G / de Jong, Hilda Ji / Pander, Jan / Overbeek, Jetty A

    BMC nephrology

    2023  Volume 24, Issue 1, Page(s) 337

    Abstract: Background: Knowledge on prevalence, comorbidities and consequences of chronic kidney disease (CKD) is mandatory to estimate the potential of cardiovascular risk management on a population level. We studied the prevalence of CKD with or without type 2 ... ...

    Abstract Background: Knowledge on prevalence, comorbidities and consequences of chronic kidney disease (CKD) is mandatory to estimate the potential of cardiovascular risk management on a population level. We studied the prevalence of CKD with or without type 2 diabetes mellitus (T2D) and/or heart failure and its cardiorenal complications in The Netherlands.
    Methods: A descriptive cross-sectional and longitudinal cohort study was performed, using data from the Dutch PHARMO Data Network. Prevalence of CKD at a single time point was determined by a recorded diagnosis or by ≥ 2 estimated glomerular filtration rate (eGFR) measurements and urine albumin/creatinine ratio (UACR) that define CKD. A representative group of adults with CKD was included in a longitudinal analysis to study cardiorenal complications. Those were followed until first complication, end of study or death, whichever occurred first.
    Results: The prevalence of CKD was 8.9% in a representative population of 2,187,962 adult Dutch individuals. The average age of persons with CKD was 72 years, 57% were female, 19.9% had T2D, 7.7% heart failure, and 3.0% both T2D and heart failure. In the longitudinal analysis, cerebrovascular events (11/1,000 person-years), hospitalizations for heart failure (10/1,000 person-years), myocardial infarction (5.5/1,000 person-years), and hospitalization for CKD (6.2/1,000 person-years) were the most common first cardiorenal complications. People with CKD with T2D and/or heart failure generally had higher rates of cardiovascular or renal complications or mortality than people with CKD without these comorbidities.
    Conclusion: The prevalence of CKD in The Netherlands is 8.9%. People with T2D or heart failure, or both, in addition to CKD, had numerically higher mortality and cardiorenal complication rates than people without these comorbidities. Optimizing up-to-date cardiovascular risk management in these high-risk individuals may provide health benefits.
    MeSH term(s) Adult ; Humans ; Female ; Aged ; Male ; Diabetes Mellitus, Type 2/complications ; Prevalence ; Longitudinal Studies ; Cross-Sectional Studies ; Netherlands/epidemiology ; Renal Insufficiency, Chronic/diagnosis ; Heart Failure/epidemiology ; Heart Failure/complications ; Glomerular Filtration Rate ; Cardiovascular Diseases/etiology
    Language English
    Publishing date 2023-11-13
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041348-8
    ISSN 1471-2369 ; 1471-2369
    ISSN (online) 1471-2369
    ISSN 1471-2369
    DOI 10.1186/s12882-023-03384-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top